Spectrum Pharmaceuticals Joins NASDAQ Biotechnology Index
SPPI | Quote | Chart | News | PowerRating -- Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, announced that it has been selected for addition to the NASDAQ Biotechnology Index.
The Company is now a component of the NASDAQ Biotechnology Index, the Russell 3000, Russell 2000, and Russell Global Indexes.
"We are pleased to be added to the NASDAQ Biotechnology Index, as it adds greater visibility for Spectrum Pharmaceuticals," said Rajesh C. Shrotriya, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "With two marketed drugs, one late stage drug recruiting patients into registrational pivotal trials, a strong team of committed professionals, and a strong financial position, we believe we are well-positioned to deliver outstanding value to our shareholders."
All securities are classified according to the Industry Classification Benchmark (ICB) as either biotechnology or pharmaceutical. The securities that meet the classification criteria then must meet other Index eligibility criteria including listing on the NASDAQ Global Market or the NASDAQ Global Select Market and meeting minimum requirements for market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November.
((Comments on this story may be sent to health@closeupmedia.com))
For full details on Spectrum Pharm Inc (SPPI) SPPI. Spectrum Pharm Inc (SPPI) has Short Term PowerRatings at TradingMarkets. Details on Spectrum Pharm Inc (SPPI) Short Term PowerRatings is available at This Link.
- BiomedReports: News and FDA Updates for Poniard (Nasdaq:PARD), Spectrum (Nasdaq:SPPI) - 02/08/10
- TopoTarget signs co-development and commercialization agreement with Spectrum Pharmaceuticals - 02/05/10
- Daytradersdigest.com: SFIO & SPPI - 02/05/10
- Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference in New York City on Tuesday, February 9th - 02/05/10
- TopoTarget signs co-development and commercialization agreement with Spectrum Pharmaceuticals - 02/03/10
- More News >>


